Trial Profile

A phase 3 trial of EDG-7500 in patients with obstructive and non-obstructive hypertrophic cardiomyopathy

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 14 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EDG-7500 (Primary)
Indications Hypertrophic cardiomyopathy
Focus Registrational; Therapeutic Use

Most Recent Events

14 Apr 2025 New trial record
02 Apr 2025 According to a Edgewise Therapeutics media release, the company has announced the pricing of its 9,935,419 shares and anticipates gross proceeds from the offering to be approximately $200 million. The company intends to use the net proceeds from this offering to support many research activities along with the advancement of this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com